Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

McMaster University

$17,500.00

FIXa protection from heparin-antithrombin inhibition when incorporated into the intrisic tenase complex

EF 2009-10

Résumé
The clotting system keeps our blood fluid under normal conditions, but can rapidly form a clot at sites of injury in order to stop bleeding. Rapid clot formation depends on a series of reactions wherein one clotting enzyme activates another until a clot forms. It is important to study how blood clotting is controlled because defective blood clot formation leads to haemophilia, while excessive blood clot formation in the heart or brain is the cause of most heart attacks and strokes. Heparin and its smaller derivatives (fondaparinux and low-molecular weight heparin) are blood-thinning drugs that are used to prevent or treat excessive blood clotting. They work by enhancing the activity of antithrombin, one of the most important natural inhibitors of clotting enzymes in blood. However, heparin has many limitations: it may not be able to stop the growth of clots that have already formed, and clots can recur when heparin treatment is stopped. My work is aimed at understanding why heparin has these limitations. My project concentrates on factor IXa, a clotting enzyme that is critical in the positive feedback loop for clot formation. Although there is good evidence that heparin promotes the inactivation of clotting enzymes that are free in solution, it not be able to inhibit enzymes that are bound to the surface of cells like platelets. This is a problem because the most efficient promoters of blood clotting in the body are bound to platelets. We think that platelet-bound factor IXa is protected from inhibition, which may explain some of the clinical limitations of heparin. Studying why heparin is limited in its capacity to fully block clotting will help us to better understand how clots form and open the door to the development of new blood thinners that overcome the limitations of heparin. These new drugs are can improve the prevention and treatment of heart attacks and strokes, the number one cause of death and disability in Canada and worldwid.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
199647
Name
Yeh Calvin H
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
FIXa protection from heparin-antithrombin inhibition when incorporated into the intrisic tenase complex
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anticoagulants; Blood; Blood Clotting Factors; Blood Coagulation; Cardiovascular; Enzyme Kinetics; Fondaparinux; Heparin; Low Molecular Weight Heparin; Protein Chemistry; Thrombosis
Abstract
The clotting system keeps our blood fluid under normal conditions, but can rapidly form a clot at sites of injury in order to stop bleeding. Rapid clot formation depends on a series of reactions wherein one clotting enzyme activates another until a clot forms. It is important to study how blood clotting is controlled because defective blood clot formation leads to haemophilia, while excessive blood clot formation in the heart or brain is the cause of most heart attacks and strokes. Heparin and its smaller derivatives (fondaparinux and low-molecular weight heparin) are blood-thinning drugs that are used to prevent or treat excessive blood clotting. They work by enhancing the activity of antithrombin, one of the most important natural inhibitors of clotting enzymes in blood. However, heparin has many limitations: it may not be able to stop the growth of clots that have already formed, and clots can recur when heparin treatment is stopped. My work is aimed at understanding why heparin has these limitations. My project concentrates on factor IXa, a clotting enzyme that is critical in the positive feedback loop for clot formation. Although there is good evidence that heparin promotes the inactivation of clotting enzymes that are free in solution, it not be able to inhibit enzymes that are bound to the surface of cells like platelets. This is a problem because the most efficient promoters of blood clotting in the body are bound to platelets. We think that platelet-bound factor IXa is protected from inhibition, which may explain some of the clinical limitations of heparin. Studying why heparin is limited in its capacity to fully block clotting will help us to better understand how clots form and open the door to the development of new blood thinners that overcome the limitations of heparin. These new drugs are can improve the prevention and treatment of heart attacks and strokes, the number one cause of death and disability in Canada and worldwid.
Competitiondate
201002
Approvedterm2
1 yr 0 mth
Pinamesdelim
Yeh, Calvin H
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~